Literature DB >> 21062922

PET/CT characteristics of isolated bone metastases in hepatocellular carcinoma.

Chi-Lai Ho1, Sirong Chen, Thomas Kam Chau Cheng, Yim Lung Leung.   

Abstract

PURPOSE: To compare the prognostic implications and positron emission tomography (PET)/computed tomography (CT) characteristics of isolated bone metastasis secondary to hepatocellular carcinoma (HCC) with those of HCC metastases to bone and other sites.
MATERIALS AND METHODS: This study was approved by the institutional ethics committee, and informed consent was obtained from all patients. Extrahepatic metastases were diagnosed in 257 patients with HCC by using dual-tracer (carbon 11 [(11)C] acetate and fluorine 18 fluorodeoxyglucose [FDG]) PET/CT. Metastatic bone lesions were identified with visual inspection and semiquantitative assessment and confirmed with histopathologic examination and/or supported by findings at other radiologic examinations or serial PET/CT.
RESULTS: The frequency of bone metastasis from HCC was 19% (49 of 257 patients; eight patients had histopathologic proof and 41 had imaging proof). Metastasis isolated to bone (group 1, 30 of 257 patients [12%]) was more common than metastasis to bone and other sites (group 2, 19 of 257 patients [7%]). At lesion-based analysis of group 1 (71 index lesions; mean lesion size ± standard deviation, 3.25 cm ± 1.88), (11)C acetate PET was more sensitive than FDG PET (93% [66 of 71 lesions] vs 62% [44 of 71 lesions], respectively; P < .05). The combined sensitivity was 97% (69 of 71 lesions) with dual-tracer PET and 72% (51 of 71 lesions) with CT. At patient-based analysis, (11)C acetate PET had an incremental value of 23% (seven of 30 patients) over FDG PET. At lesion-based analysis of group 2, FDG PET was more sensitive than (11)C acetate PET (87% [33 of 38 lesions] vs 50% [19 of 38 lesions], respectively; P < .05). Tracer avidities of metastatic bone lesions were closely correlated with that of their corresponding primary HCC tumors. The median survival time was longer in group 1 than in group 2 (18 months vs 11 months, respectively; P < .05).
CONCLUSION: Isolated bone metastasis from HCC may not be as uncommon as previously believed. The detection of these metastases can be significantly enhanced with (11)C acetate PET compared with FDG PET alone. Identification of this group of patients also seems to have prognostic importance. © RSNA, 2010.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21062922     DOI: 10.1148/radiol.10100672

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  13 in total

Review 1.  The emerging role of positron emission tomography in hepatocellular carcinoma.

Authors:  Suraiya R Dubash; Oluwagbemiga A Idowu; Rohini Sharma
Journal:  Hepat Oncol       Date:  2015-04-27

2.  Animal and cellular models of hepatocellular carcinoma bone metastasis: establishment and characterisation.

Authors:  Rui Hou; Yu-Wei Wang; Hui-Fang Liang; Zhan-Guo Zhang; Zhi-Min Liu; Bin-Hao Zhang; Bi-Xiang Zhang; Xiao-Ping Chen
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-28       Impact factor: 4.553

3.  A clinicopathological model to predict bone metastasis in hepatocellular carcinoma.

Authors:  Zuo-Lin Xiang; Zhao-Chong Zeng; Jia Fan; Wei-Zhong Wu; Jian He; Hai-Ying Zeng; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-14       Impact factor: 4.553

4.  Evaluation of Bone Metastasis from Hepatocellular Carcinoma Using (18)F-FDG PET/CT and (99m)Tc-HDP Bone Scintigraphy: Characteristics of Soft Tissue Formation.

Authors:  Hyo Jung Seo; Yun Jung Choi; Hyun Jeong Kim; Yong Hyu Jeong; Arthur Cho; Jae Hoon Lee; Mijin Yun; Hye Jin Choi; Jong Doo Lee; Won Jun Kang
Journal:  Nucl Med Mol Imaging       Date:  2011-08-05

5.  GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker.

Authors:  Kátia C Carvalho; Isabela W Cunha; Rafael M Rocha; Fernanda R Ayala; Mariana M Cajaíba; Maria D Begnami; Rafael S Vilela; Geise R Paiva; Rodrigo G Andrade; Fernando A Soares
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 6.  Bone metastasis of hepatocellular carcinoma: facts and hopes from clinical and translational perspectives.

Authors:  Zhao Huang; Jingyuan Wen; Yufei Wang; Shenqi Han; Zhen Li; Xuemei Hu; Dongling Zhu; Zhenxiong Wang; Junnan Liang; Huifang Liang; Xiao-Ping Chen; Bixiang Zhang
Journal:  Front Med       Date:  2022-07-19       Impact factor: 9.927

7.  Pelvic bone fractures mimicking bone metastases in a patient with hepatitis B virus-associated liver cirrhosis and hepatocellular carcinoma.

Authors:  Dong Hyeon Lee; Eun Sun Jang; Hong Sang Oh; Kwang Hyun Chung; Eun Hyo Jin; Eu Jeong Ku; Eun Roh
Journal:  Korean J Intern Med       Date:  2012-11-27       Impact factor: 2.884

8.  Nuclear imaging for functional evaluation and theragnosis in liver malignancy and transplantation.

Authors:  Jae Seon Eo; Jin Chul Paeng; Dong Soo Lee
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

9.  Value of Bone Scans in Work-up of Patients With Hepatocellular Carcinoma for Liver Transplant.

Authors:  Numan Kutaiba; Zaid Ardalan; Kurvi Patwala; Eddie Lau; Mark Goodwin; Paul Gow
Journal:  Transplant Direct       Date:  2018-11-23

10.  A randomized trial of conventional fraction versus hypofraction radiotherapy for bone metastases from hepatocellular carcinoma.

Authors:  Jian He; Shiming Shi; Luxi Ye; Guifen Ma; Xiangou Pan; Yan Huang; Zhaochong Zeng
Journal:  J Cancer       Date:  2019-07-08       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.